Sex-dependent correlation between survival and expression of genes related to the circadian oscillator in patients with colorectal cancer

References

• Albrecht U. 2012. Timing to perfection : The biology of central and peripheral circadian clocks. Neuron. 74(2):246–60.
   PubMed Web of Science ®Google Scholar
• Amos-Landgraf JM, Heijmans J, Wielenga MC, Dunkin E, Krentz KJ, Clipson L, Ederveen AG, Groothuis PG, Mosselman S, Muncan V, et al. 2014. Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones. Proc Natl Acad Sci USA. 111(46):16514–165199. doi:10.1073/pnas.1323064111.
   PubMed Web of Science ®Google Scholar
• Bendardaf R, El-Serafi A, Syrjänen K, Collan Y, Pyrhönen S. 2017. The effect of vascular endothelial growth factor-1 expression on survival of advanced colorectal cancer patients. Libyan J Med. 12(1):1290741. doi:10.1080/19932820.2017.1290741.
   Google Scholar
• Brenner H, Hoffmeister M, Arndt V, Haug U. 2007. Gender differences in colorectal cancer : Implications for age at initiation of screening. Br J Cancer. 96(5):828–31.
   PubMed Web of Science ®Google Scholar
• Cadenas C, van de Sandt L, Edlund K, Lohr M, Hellwig B, Marchan R, Schmidt M, Rahnenfuhrer J, Oster H, Hengstler JG. 2014. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle. 13(20):3282–91.
   PubMed Web of Science ®Google Scholar
• Cai W, Rambaud J, Teboul M, Masse I, Benoit G, Gustafsson JA, Delaunay F, Laudet V, Pongratz I. 2008. Expression levels of estrogen receptor beta are modulated by components of the molecular clock. Mol Cell Biol. 28(2):784–93.
   PubMed Web of Science ®Google Scholar
• Campbell-Thompson M, Lynch IJ, Bhardwaj B. 2001. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res. 61(2):632–40.
   PubMed Web of Science ®Google Scholar
• Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. 2005. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 26(7):1241–46.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Wactawski-Wende J, Rittenbaugh C, Hubbel FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, et al. 2004. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 350(10):991–1004. doi:10.1056/NEJMoa032071.
   PubMed Web of Science ®Google Scholar
• Clocchiatti A, Cora E, Zhang Y, Dotto GP. 2016. Sexual dimorphism in cancer. Nat Rev Cancer. 16(5):330–39.
   PubMed Web of Science ®Google Scholar
• Filipski E, Lévi F. 2009. Circadian disruption in experimental cancer processes. Integr Cancer Ther. 8(4):298–302.
   PubMed Web of Science ®Google Scholar
• Fu L, Pelicano H, Liu J, Huang P, Lee C. 2002. The circadian gene period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 111(1):41–50.
   PubMed Web of Science ®Google Scholar
• Gauger MA, Sancar A. 2005. Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer. Cancer Res. 65(15):6828–34.
   PubMed Web of Science ®Google Scholar
• George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, Swift RI. 2001. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia. 3(5):420–27.
   PubMed Web of Science ®Google Scholar
• Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. 2007. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 26(57):7916–20.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Dugué PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, Tumolo S, Coudert B, Iacobelli S, Smaaland R, et al. 2012. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer : a meta-analysis. Ann Oncol. 23(12):3110–16. doi:10.1093/annonc/mds148.
   PubMed Web of Science ®Google Scholar
• Gillessen S, Templeton A, Marra G, Kuo Y, Valtorta E, Shahinian VB. 2010. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst. 102(23):1760–70.
   PubMedGoogle Scholar
• Giroux V, Lemay F, Bernatchez G, Robitaille Y, Carrier JC. 2008. Estrogen receptor beta deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice. Int J Cancer. 123(2):303–11.
   PubMed Web of Science ®Google Scholar
• Gitenay D, Baron VT. 2009. Is EGR1 a potential target for prostate cancer therapy? Future Oncol. 5(7):993–1003.
   PubMed Web of Science ®Google Scholar
• Greendale GA, Edelstein S, Barrett-Connor E. 1997. Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study. J Bone Miner Res. 12(11):1833–43.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Newcomb PA, Stampfer MJ. 1999. Postmenopausal hormone therapy and the risk of colorectal cancer : A review and meta-analysis. Am J Med. 106(5):574–82.
   PubMed Web of Science ®Google Scholar
• Gu S, Papadopoulou N, Nasir O, Föller M, Alevizopoulos K, Lang F, Stournaras C. 2011. Activation of membrane androgen receptors in colon cancer inhibits the prosurvival signals Akt/Bad in vitro and in vivo and blocks migration via vinculin/actin signaling. Mol Med. 17(1–2):48–58.
   PubMed Web of Science ®Google Scholar
• Gupta V, Singh SM. 2008. Gender dimorphism of tumor growth: Role of gonadal hormones in differential regulation of apoptosis of a murine T cell lymphoma. J Biomed Sci. 15(2):147–62.
   PubMed Web of Science ®Google Scholar
• Haus EL, Smolensky MH. 2013. Shift work and cancer risk : Potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev. 17(4):273–84.
   PubMed Web of Science ®Google Scholar
• He H, Yang F, Liu X, Zeng X, Hu Q, Zhu Q, Tu B. 2007. Sex hormone ratio changes in men and postmenopausal women with coronary artery disease. Menopause. 14(3 Pt 1):385–90.
   PubMed Web of Science ®Google Scholar
• Hoffman AE, Zheng T, Ba Y, Stevens RG, Yi CH, Leaderer D, Zhu Y. 2010a. Phenotypic effects of the circadian gene Cryptochrome 2 on cancer-related pathways. BMC Cancer. 10:110.
   PubMed Web of Science ®Google Scholar
• Hoffman AE, Zheng T, Ch-H Y, Stevens RG, Ba Y, Zhang Y, Leaderer D, Holford T, Hansen J, Zhu Y. 2010b. The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling. Cancer Prev Res. 3(4):539–48.
   PubMed Web of Science ®Google Scholar
• Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, Wang X, Wang Z, Cornelissen-Guillaume G, Halberg F. 2006. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci. 97(7):589–96.
   PubMed Web of Science ®Google Scholar
• Kang TH, Lindsey-Boltz LA, Reardon JT, Sancar A. 2010. Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proc Natl Acad Sci USA. 107:4890−4895.
   PubMed Web of Science ®Google Scholar
• Karatsoreos IN, Butler MP, Lesauter J, Silver R. 2011. Androgens modulate structure and function of the suprachiasmatic nucleus brain clock. Neuroendocrinology. 152(52):1970–78.
   Google Scholar
• Kawamura M, Tasaki H, Misawa I, Chu G, Yamauchi N, Hattori MA. 2014. Contribution of testosterone to the clock system in rat prostate mesenchyme cells. Andrology. 2(2):225–33.
   PubMed Web of Science ®Google Scholar
• Koutras A, Kotoula V, Fountzilas G. 2015. Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer. Pharmacogenomics. 16(1):79–94.
   PubMed Web of Science ®Google Scholar
• Koyanagi S, Kuramoto Y, Nakagawa H, Aramaki H, Ohdo S, Soeda S, Shimeno H. 2003. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res. 63(21):7277–83.
   PubMed Web of Science ®Google Scholar
• Krones-Herzig A, Mittal S, Yule K, Liang H, English C, Urcis R, Soni T, Adamson ED, Mercola D. 2005. Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res. 65(12):5133–43.
   PubMed Web of Science ®Google Scholar
• Lévi F, Focan C, Karaboué A, de la Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S. 2007. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 59(9–10):1015–35.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Natoni A, Keane M, Samali A, Szegezdi E. 2010. Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. Br J Cancer. 102(4):754–64.
   PubMed Web of Science ®Google Scholar
• Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. 2003. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 302(5643):255–59.
   PubMed Web of Science ®Google Scholar
• Mazzoccoli G, Colangelo T, Panza A, Rubino R, De Cata A, Tiberio C, Valvano MR, Pazienza V, Merla G, Augello B, et al. 2016. Deregulated expression of cryptochrome genes in human colorectal cancer. Mol Cancer. 15:6.
   PubMed Web of Science ®Google Scholar
• Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, Biscaglia G, Tavano F, Di Sebastiano P, Andriulli A, et al. 2011. Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int. 28(10):841–51. doi:10.3109/07420528.2011.615182.
   PubMed Web of Science ®Google Scholar
• Miki T, Matsumoto T, Zhao Z, Lee CC. 2013. p53 regulates Period2 expression and the circadian clock. Nat Commun. 4:2444.
   PubMed Web of Science ®Google Scholar
• Mostafaie N, Kállay E, Sauerzapf E, Bonner E, Kriwanek S, Cross HS, Huber KR, Krugluger W. 2009. Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Mol Carcinog. 48(7):642–47.
   PubMed Web of Science ®Google Scholar
• Myung DS, Park YL, Kim N, Chung CY, Park HC, Kim JS, Cho SB, Lee WS, Lee JH, Joo YE. 2014. Expression of early growth response-1 in colorectal cancer and its relation to tumor cell proliferation and apoptosis. Oncol Rep. 31(2):788–94.
   PubMed Web of Science ®Google Scholar
• Nakamura TJ, Moriya T, Inoue S, Shimazoe T, Watanabe S, Ebihara S, Shinohara K. 2005. Estrogen differentially regulates expression of Per1 and Per2 genes between central and peripheral clocks and between reproductive and nonreproductive tissues in female rats. J Neurosci Res. 82(5):622–30.
   PubMed Web of Science ®Google Scholar
• Nakamura TJ, Shinohara K, Funabashi T, Kimura F. 2001. Effect of estrogen on the expression of Cry1 and Cry2 mRNAs in the suprachiasmatic nucleus of female rats. Neurosci Res. 41(3):251–55.
   PubMed Web of Science ®Google Scholar
• Oshima T, Takenoshita S, Akaike M, Kunisaki C, Fujii S, Nozaki A, Numata K, Shiozawa M, Rino Y, Tanaka K, et al. 2011. Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. Oncol Rep. 25(5):1439–46. doi:10.3892/or.2011.1207.
   PubMed Web of Science ®Google Scholar
• Rudolph A, Toth C, Hoffmeister M, Roth W, Herpel E, Jansen L, Marx A, Brenner H, Chang-Claude J. 2012. Expression of oestrogen receptor β and prognosis of colorectal cancer. Br J Cancer. 107(5):831–39.
   PubMed Web of Science ®Google Scholar
• Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Fuchs CS, Colditz GA. 2003. Night-shift work and risk of colorectal cancer in the nurses’ health study. J Natl Cancer Inst. 95(11):825–28.
   PubMedGoogle Scholar
• Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA. 2001. Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst. 93(20):1563–68.
   PubMedGoogle Scholar
• Sotak M, Polidarová L, Ergang P, Sumova A, Pacha J. 2013. An association between clock genes and clock-controlled cell cycle genes in murine colorectal tumors. Int J Cancer. 132(5):1032–41.
   PubMed Web of Science ®Google Scholar
• Storcelova M, Vician M, Reis R, Zeman M, Herichova I. 2013. Expression of cell cycle regulatory factors hus1, gadd45a, rb1, cdkn2a and mre11a correlates with expression of clock gene per2 in human colorectal carcinoma tissue. Mol Biol Rep. 40(11):6351–61.
   PubMed Web of Science ®Google Scholar
• Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Benbrahim-Tallaa L, Cogliano V, WHO International Agency For Research on Cancer Monograph Working Group. 2007. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 8(12):1065–66. doi:10.1016/S1470-2045(07)70373-X.
   PubMed Web of Science ®Google Scholar
• Tao W, Wu J, Zhang Q, Lai SS, Jiang S, Jiang C, Xu Y, Xue B, Du J, Li CJ. 2015. EGR1 regulates hepatic clock gene amplitude by activating Per1 transcription. Sci Rep. 16(5):15212.
   Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 2015. Global cancer statistics, 2012. CA Cancer J Clin. 65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hua L, Lu C, Chen Z. 2011. Expression of circadian clock gene human Period2 (hPer2) in human colorectal carcinoma. World J Surg Oncol. 9:166.
   PubMed Web of Science ®Google Scholar
• Weige CC, Allred KF, Allred CD. 2009. Estradiol alters cell growth in nonmalignant colonocytes and reduces the formation of preneoplastic lesions in the colon. Cancer Res. 69(23):9118–24.
   PubMed Web of Science ®Google Scholar
• Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP. 1999. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer. 81(6):845–50.
   PubMed Web of Science ®Google Scholar
• Wood PA, Yang X, Taber A, Oh EY, Ayers SE, Al-Assaad Z, Carnevale K, Berger FG, Peña MM, Hrushesky WJ. 2008. Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res. 6(11):1786–93.
   PubMed Web of Science ®Google Scholar
• Yang X, Wood PA, Ansell C, Hrushesky WJ. 2009. Circadian time-dependent tumor suppressor function of period genes. Integr Cancer Ther. 8(4):309–16.
   PubMed Web of Science ®Google Scholar
• Yu H, Meng X, Wu J, Pan C, Ying X, Zhou Y, Liu R, Huang W. 2013. Cryptochrome 1 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer. PLoS One. 8(4):e61679.
   PubMed Web of Science ®Google Scholar
• Zeman M, Vician M, Monosikova J, Reis R, Herichova I. 2008. Deregulated expression of the per2 gene in human colorectal carcinoma. Mol Med Rep. 1(4):599–603.
   PubMed Web of Science ®Google Scholar
• Zhao H, Zeng ZL, Yang J, Jin Y, Qiu MZ, Hu XY, Han J, Liu KY, Liao JW, Xu RH, et al. 2014. Prognostic relevance of Period1 (Per1) and Period2 (Per2) expression in human gastric cancer. Int J Clin Exp Pathol. 7(2):619–30.
   PubMed Web of Science ®Google Scholar